The company's platform allows for the creation of inhibitors that target the immunoproteasome and modulate specific immune cell types, helping patients recover from autoimmune and inflammatory diseases. Orange Grove Bio partners with research universities to advance preclinical biotech programs in oncology, leveraging its venture capital and drug development expertise to benefit patients and build biotech ecosystems.